Tolerability of first-line therapy for metastatic renal cell carcinoma

Cancer Treatment Reviews

Volumn 35, Issue 3, 2009, Pages 297-307

  Porta, Camillo ^a   Szczylik, Cezary ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Bevacizumab; Interferon; Renal cell carcinoma; Side effects; Sunitinib; Temsirolimus; Tolerability; VEGF

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; HYDRALAZINE; LACTATE DEHYDROGENASE; NEBIVOLOL; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FLU LIKE SYNDROME; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT MONITORING; PROGNOSIS; PROTEINURIA; RASH; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COAGULATION DISORDERS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; HYPOTHYROIDISM; INDOLES; INTERFERONS; KIDNEY NEOPLASMS; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; WOUND HEALING;

EID: 64549104195     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.12.003     Document Type: Review

References (115)

1. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
2. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
3. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
4. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
5. Motzer R.J., Escudier B.J., Oudard A., et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study. J Clin Oncol 26 (2008) 1009s [Abstract LBA5026]
6. Jacobsen J., Grankvist K., Rasmuson T., Bergh A., Landberg G., and Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93 (2004) 297-302
7. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl. 3 (2005) 4-10
8. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
9. Mendel D.B., Laird A.D., Xin X.H., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
10. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
11. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
12. Del Bufalo D., Ciuffreda L., Triscinoglio D., et al. Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66 (2006) 5549-5554
13. Figlin R.A., Hutson T.E., Tomczak P., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 May 20 Suppl. (2008) 256s [Abstract 5024]
14. Rini B, Halabi S, Rosenberg J, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma. Presented at: Genitourinary Cancers Symposium 14-16 February 2008;267 [Abstract 350].
15. Dutcher J.P., Szczylik C., Tannir N., et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25 June 20 Suppl. (2007) 243s [Abstract 5033]
16. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
17. Szczylik C., Demkow T., Staehler M., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 25 (2007) 241s [Abstract 5025]
18. Hutson TE. Sequentisl drug therapy for metastatic renal cell cancer: which patients and what order of agents? Proceedings of Genitourinary Cancers Symposium 14-16 February 2008. p. 92-93.
19. Patil S., Ishill N., Deluca J., and Motzer R.J. Trends in Memorial Sloan-Kettering Cancer Center risk group distribution according to treatment year for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 May 20 Suppl. (2008) 272s [Abstract 5092]
20. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
21. Bukowski R.M., Kabbinavar F.F., Figlin R.A., et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25 (2007) 4536-4541
22. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
23. Kamba T., and McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96 (2007) 1788-1795
24. Widakowich C., De Castro G., De Azambuja E., Dinh P., and Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12 (2007) 1443-1455
25. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4593-4599
26. Yang J.C. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10 (2004) 6367S-6370S
27. Avastin SmPC; 2008.
28. Slaton J.W., Perrotte P., Inoue K., Dinney C.P., and Fidler I.J. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5 (1999) 2726-2734
29. Melichar B., Koralewski P., Ravaud A., et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 19 (2008) 1470-1476
30. Motzer R.J., Figlin R.A., Hutson T.E., et al. Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. J Clin Oncol 25 June 20 Suppl. (2007) 241s [Abstract 5024]
31. Houk H.E., Bello C.L., Michaelson M.D., et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 25 June 20 Suppl. (2007) 241s [Abstract 5027]
32. Felmeden D.C., Spencer C.G.C., Belgore F.M., Blann A.D., Beevers D.G., and Lip G.Y.H. Endothelial damage and angiogenesis in hypertensive patients: Relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16 (2003) 11-20
33. Wolf S., and Risler T. Are all antihypertensive drugs renoprotective?. Herz 29 (2004) 248-254
34. McNeely W., and Goa K.L. Nebivolol in the management of essential hypertension: a review. Drugs 57 (1999) 633-651
35. Gray C.L., and Ndefo U.A. Nebivolol: a new antihypertensive agent. Am J Health Syst Pharm 65 (2008) 1125-1133
36. Eming S.A., and Krieg T. Molecular mechanisms of VEGF-A action during tissue repair. J Investig Dermatol Symp Proc 11 (2006) 79-86
37. ® (sunitinib). Summary of Product Characteristics. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid= 18531 [serial online] 2008 Aug 22 [cited 2008 Oct 7]. Available from: URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid= 18531.
38. Saif M.W., and Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 5 (2006) 553-566
39. Gore M., Szczylik C., Porta C., et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis. Eur J Cancer Suppl 5 (2007) 299 [Abstract O4503]
40. Pouessel D., and Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53 (2008) 376-381
41. Porta C., Imarisio I., Paglino C., Re: Damien P., and Stephane C. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53 (2008) 1092-1093
42. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26 (2008) 1830-1835
43. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
44. Berry S., Cunningham D., Michael M., et al. Preliminary efficacy of bevacizumab with first-line folfox, xelox, folfiri and fluoropyrimidines for mCRC: First BEAT trial. Eur J Cancer Suppl 5 (2007) 241
45. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280 (2001) C1375-C1386
46. Spivak J.L. Polycythemia vera: myths, mechanisms, and management. Blood 100 (2002) 4272-4290
47. Tam B.Y., Wei K., Rudge J.S., et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12 (2006) 793-800
48. Sufrin G., Chasan S., Golio A., and Murphy G.P. Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol 7 (1989) 158-171
49. Kilickap S., Abali H., and Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 21 (2003) 3542
50. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
51. Kitamoto Y., Tokunaga H., Miyamoto K., and Tomita K. VEGF is an essential molecule for glomerular structuring. Nephrol Dial Transplant 17 (2002) 25-27
52. Martel C.L., Presant C.A., Ebrahimi B., et al. Bevacizumab-related toxicities: association of hypertension and proteinuria. Commun Oncol 3 (2006) 90-93
53. Kamba T., Tam B.Y.Y., Hashizume H., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290 (2006) H560-H576
54. Wood L.S. Managing the side effects of sorafenib and sunitinib. Commun Oncol 3 (2006) 558-562
55. Kollmannsberger C., Soulieres D., Wong R., Scalera A., Gaspo R., and Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1 (2007) S41-S54
56. Rosenbaum S.E., Wu S., Newman M.A., West D.P., Kuzel T., and Lacouture M.E. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 16 (2008) 557-566
57. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
58. Tsai K.Y., Yang C.H., Kuo T.T., Hong H.S., and Chang J.W.C. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 24 (2006) 5786-5788
59. Lacouture M.E., Reilly L.M., Gerami P., and Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19 (2008) 1955-1961
60. Kondagunta G.V., Hudes G., Figlin R., et al. Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): Results of a dose-finding study. J Clin Oncol 25 June 20 Suppl. (2007) 260s [Abstract 5101]
61. Zurita A.J., Shore N.D., Kozloff M., et al. Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa). J Clin Oncol 25 June 20 Suppl. (2007) 268s [Abstract 5134]
62. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18 (2004) 338-340
63. Robert C., Spatz A., Faivre S., Armand J.P., and Raymond E. Tyrosine kinase inhibition and grey hair. Lancet 361 (2003) 1056
64. Botchkareva N.V., Khlgatian M., Longley B.J., Botchkarev V.A., and Gilchrest B.A. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 15 (2001) 645-658
65. Feldman D.R., Martorella A.J., Robbins R.J., and Motzer R.J. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 (2007) 974-975
66. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 (2007) 81-83
67. Wolter P., Stefan C., Decallone B., et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J Clin Invest 26 May 20 Suppl. (2008) 280s [Abstract 5126]
68. Schoeffski P., Wolter P., Himpe U., et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J Clin Oncol 24 (2006) 143S
69. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 (2006) 660-664
70. Baffert F., Le T., Sennino B., et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290 (2006) H547-H559
71. Wolter P., Dumez H., and Schoffski P. Sunitinib and hypothyroidism. N Engl J Med 356 (2007) 1580
72. Sutent prescribing information; 2008.
73. Sartore-Bianchi A., Soriani A., Mattioni R., Vaglio A., Buzio C., and Porta C. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. Oncol Rep 12 (2004) 855-859
74. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007) 2011-2019
75. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate - A multitargeted receptor tyrosine kinase inhibitor. Cancer 112 (2008) 2500-2508
76. Telli M.L., Witteles R.M., Fisher G.A., and Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19 (2008) 1613-1618
77. Machiels J.P., Bletard N., Pirenne P., Jacquet L., Bonbled F., and Duck L. Acute cardiac failure after sunitinib. Ann Oncol 19 (2008) 598-599
78. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26 (2008) 5204-5212
79. Force T., Krause D.S., and Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7 (2007) 332-344
80. Sarzani R., Arnaldi G., and Chobanian A.V. Hypertension-induced changes of platelet-derived growth-factor receptor expression in rat aorta and heart. Hypertension 17 (1991) 888-895
81. Liu J., Wu L.L., Li L., Zhang L., and Song Z.E. Growth-promoting effect of platelet-derived growth factor on rat cardiac myocytes. Regul Pept 127 (2005) 11-18
82. Ferrara N., Carver-Moore K., Chen H., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
83. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
84. Gerber H.P., Malik A.K., Solar G.P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
85. Kirkwood J.M., Bender C., Agarwala S., et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20 (2002) 3703-3718
86. Muss H.B., Costanzi J.J., Leavitt R., et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 5 (1987) 286-291
87. Escudier B., Cosaert J., and Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics: Targets and Therapy 2 (2008) 517-530
88. Malik U.R., Makower D.F., and Wadler S. Interferon-mediated fatigue. Cancer 92 (2001) 1664-1668
89. Kennedy R.L., and Jones T.H. Cytokines in endocrinology: their roles in health and in disease. J Endocrinol 129 (1991) 167-178
90. Jones T.H., Wadler S., and Hupart K.H. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol 25 (1998) 54-63
91. Mock V. Fatigue management: evidence and guidelines for practice. Cancer 92 (2001) 1699-1707
92. Koubovec D., Berghe W.V., Vermeulen W., Haegeman G., and Hapgood J.P. Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol 221 (2004) 75-85
93. Mantovani G., Maccio A., Massa E., and Maddeddu C. Managing cancer-related anorexia/cachexia. Drugs 61 (2001) 499-514
94. Mantovani G., Maccio A., Maddeddu C., et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Oncogene 24 (2008) 305-313
95. Wang Q., Miyakawa Y., Fox N., and Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 96 (2000) 2093-2099
96. Yamane A., Nakamura T., Suzuki H., et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 112 (2008) 542-550
97. Finazzi G., and Barbui T. Expertise-based management in essential thrombocythemia and polycythemia vera. Cancer J 13 (2007) 372-376
98. Raison C.L., Demetrashvili M., Capuron L., and Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19 (2005) 105-123
99. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry; in press, doi:10.1038/mp.2008.58.
100. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., and Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiat 160 (2003) 1342-1345
101. Hauschild A., Gogas H., Tarhini A., et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112 (2008) 982-994
102. Bellmunt J., Szczylik C., Feingold J., Strahs A., and Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19 (2008) 1387-1392
103. Bhojani N., Jeldres C., Patard J.J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53 (2008) 917-930
104. Taha C., Liu Z., Jin J., Al-Hasani H., Sonenberg N., and Klip A. Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem 274 (1999) 33085-33091
105. Huffman T.A., Mothe-Satney I., and Lawrence J.C. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci USA 99 (2002) 1047-1052
106. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
107. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
108. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
109. Merchan J.R., Liu G., Fitch T., et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 25 (2007) 243s [Abstract 5034]
110. Whorf R.C., Hainsworth J., Spigel D.R., et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 26 May 20 Suppl. (2008) 252s [Abstract 5010]
111. Sosman J., Flaherty K., Atkins M., et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 26 May 20 Suppl. (2008) 252s [Abstract 5011]
112. Ryan CW, Curti BD, Pattee KJ, Besaw L, Beer TM, Fisher B. A dose-escalation phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). Presented at: 2008 Genitourinary Cancers Symposium; 14-16 February; San Francisco, Ca; 2008 [Abstract 361].
113. Michaelson M, Schwarzberg A, Ryan D, et al. A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. Presented at: 2008 Genitourinary Cancers Symposium; 14-16 February; San Francisco, Ca; 2008 [Abstract 362].
114. Pandya SS, Mier JW, Cho D, McDermott DF. The role of adding gemcitabine at time of sunitinib resistance in patients with metastatic renal cell cancer. Presented at: 2008 Genitourinary Cancers Symposium; 14-16 February; San Francisco, Ca; 2008 [Abstract 380].
115. Feldman D.R., Ginsberg M., Baum C.M., et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 26 May 20 Suppl. (2008) 274s [Abstract 5100]